Showing 1 posts of 1 posts found.
On 1 August 2023, Revolution Medicines signed an official agreement confirming the acquisition of the biopharmaceutical company EQRx. The deal …
NEC joins €6.5m European project using AI for pandemic vaccine design
The evidence bar impacting UK medical cannabis access
Survey highlights mental health burden among rare disease patients and families
Addressing the rheumatic disease diagnostic gap in primary care
How chronic disease creates opportunity on diagnostic and therapeutic pipelines